drugset
drugset / Trial / NCT03943992

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

NCT03943992 ↗

Phase 3 Completed 170 enrolled Yooyoung Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).

Timeline

Start
2019-01-29
Primary completion
2020-01-31
Completion
2020-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject YYD601 Small molecule 40 mg —

Indications

esophagitis